Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial

Sabico, S., Al-Mashharawi, A., Al-Daghri, N.M., Yakout, S., Alnaami, A.M., Alokail, M.S. and McTernan, P.G. ORCID: 0000-0001-9023-0261, 2017. Effects of a multi-strain probiotic supplement for 12 weeks in circulating endotoxin levels and cardiometabolic profiles of medication naïve T2DM patients: a randomized clinical trial. Journal of Translational Medicine, 15, p. 249. ISSN 1479-5876

[img]
Preview
Text
10074_McTernan.pdf - Published version

Download (1MB) | Preview

Abstract

Background: The present randomized clinical trial characterized the beneficial effects of a multi-strain probiotics supplementation on improving circulating endotoxin levels (primary endpoint) and other cardiometabolic biomarkers (secondary endpoint) in patients with T2DM.
Methods: A total of 78 adult Saudi T2DM patients (naïve and without co-morbidities) participated in this clinical trial and were randomized to receive twice daily placebo or probiotics [(2.5 × 109 cfu/g) containing the following bacterial strains: Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58 (Ecologic®Barrier)] in a double-blind manner for 12 weeks. Anthropometrics and cardiometabolic profiles were obtained at baseline and after 12/13 weeks of treatment.
Results: After 12/13 weeks of intervention and using intention-to-treat analysis, no difference was noted in endotoxin levels between groups [Placebo − 9.5% vs. Probiotics − 52.2%; (CI − 0.05 to 0.36; p = 0.15)]. Compared with the placebo group however, participants in the probiotics groups had a significant but modest improvement in WHR [Placebo 0.0% vs. Probiotics 1.11%; (CI − 0.12 to − 0.01; p = 0.02)] as well as a clinically significant improvement in HOMA-IR [Placebo − 12.2% vs. Probiotics − 60.4%; (CI − 0.34 to − 0.01; p = 0.04)].
Conclusion: Using a multi-strain probiotic supplement daily for 12/13 weeks significantly improved HOMA-IR and modestly reduced abdominal adiposity among medication naïve T2DM patients.

Item Type: Journal article
Publication Title: Journal of Translational Medicine
Creators: Sabico, S., Al-Mashharawi, A., Al-Daghri, N.M., Yakout, S., Alnaami, A.M., Alokail, M.S. and McTernan, P.G.
Publisher: BioMed Central
Date: 11 December 2017
Volume: 15
ISSN: 1479-5876
Identifiers:
NumberType
10.1186/s12967-017-1354-xDOI
1354Publisher Item Identifier
Rights: © the author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
Divisions: Schools > School of Science and Technology
Depositing User: Jonathan Gallacher
Date Added: 25 Jan 2018 13:38
Last Modified: 25 Jan 2018 13:38
URI: http://irep.ntu.ac.uk/id/eprint/32545

Actions (login required)

Edit View Edit View

Views

Views per month over past year

Downloads

Downloads per month over past year